Nektar Therapeutics - NKTR Stock Forecast, Price & News

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 3 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings or view top-rated stocks.

13 equities research analysts have issued twelve-month price objectives for Nektar Therapeutics' stock. Their NKTR share price forecasts range from $3.00 to $54.00. On average, they predict the company's stock price to reach $13.17 in the next year. This suggests a possible upside of 311.5% from the stock's current price.
View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts.

Nektar Therapeutics' stock was trading at $13.51 at the start of the year. Since then, NKTR stock has decreased by 76.3% and is now trading at $3.20.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NKTR earnings forecast.

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.85) EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $0.16. The biopharmaceutical company had revenue of $21.59 million for the quarter, compared to the consensus estimate of $22.75 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 82.40% and a negative net margin of 544.77%. Nektar Therapeutics's revenue for the quarter was down 23.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.69) earnings per share.

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NKTR stock can currently be purchased for approximately $3.20.

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $599.68 million and generates $101.91 million in revenue each year. The biopharmaceutical company earns $-523,840,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis.

The company employs 740 workers across the globe.

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.